
Global EGFR-TKI Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global EGFR-TKI market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the EGFR-TKI market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the EGFR-TKI market include ArriVent Biopharma, AstraZeneca, Beacon Pharma, Boehringer Ingelheim Pharmaceuticals, Cipla, Drug International, Glenmark Pharmaceuticals, Hanmi Pharmaceutical and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for EGFR-TKI, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of EGFR-TKI, also provides the sales of main regions and countries. Of the upcoming market potential for EGFR-TKI, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the EGFR-TKI sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global EGFR-TKI market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for EGFR-TKI sales, projected growth trends, production technology, application and end-user industry.
EGFR-TKI Segment by Company
ArriVent Biopharma
AstraZeneca
Beacon Pharma
Boehringer Ingelheim Pharmaceuticals
Cipla
Drug International
Glenmark Pharmaceuticals
Hanmi Pharmaceutical
Johnson & Johnson
Mylan
Pfizer
Roche
Teva
Yuhan Corporation
Betta Pharma
Chengdu Brilliant Pharmaceuticals
Hansoh Pharma
Shanghai Allist Pharmaceuticals
Wanbang Biopharmaceuticals
EGFR-TKI Segment by Type
Afatinib
Aumolertinib
Icotinib
Osimertinib
Dacomitinib
Erlotinib
Furmonertinib
Gefitinib
Lazertinib
Other
EGFR-TKI Segment by Application
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
EGFR-TKI Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global EGFR-TKI status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions EGFR-TKI market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify EGFR-TKI significant trends, drivers, influence factors in global and regions.
6. To analyze EGFR-TKI competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global EGFR-TKI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of EGFR-TKI and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of EGFR-TKI.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the EGFR-TKI market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global EGFR-TKI industry.
Chapter 3: Detailed analysis of EGFR-TKI manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of EGFR-TKI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of EGFR-TKI in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global EGFR-TKI market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the EGFR-TKI market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for EGFR-TKI is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the EGFR-TKI market include ArriVent Biopharma, AstraZeneca, Beacon Pharma, Boehringer Ingelheim Pharmaceuticals, Cipla, Drug International, Glenmark Pharmaceuticals, Hanmi Pharmaceutical and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for EGFR-TKI, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of EGFR-TKI, also provides the sales of main regions and countries. Of the upcoming market potential for EGFR-TKI, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the EGFR-TKI sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global EGFR-TKI market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for EGFR-TKI sales, projected growth trends, production technology, application and end-user industry.
EGFR-TKI Segment by Company
ArriVent Biopharma
AstraZeneca
Beacon Pharma
Boehringer Ingelheim Pharmaceuticals
Cipla
Drug International
Glenmark Pharmaceuticals
Hanmi Pharmaceutical
Johnson & Johnson
Mylan
Pfizer
Roche
Teva
Yuhan Corporation
Betta Pharma
Chengdu Brilliant Pharmaceuticals
Hansoh Pharma
Shanghai Allist Pharmaceuticals
Wanbang Biopharmaceuticals
EGFR-TKI Segment by Type
Afatinib
Aumolertinib
Icotinib
Osimertinib
Dacomitinib
Erlotinib
Furmonertinib
Gefitinib
Lazertinib
Other
EGFR-TKI Segment by Application
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
EGFR-TKI Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global EGFR-TKI status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions EGFR-TKI market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify EGFR-TKI significant trends, drivers, influence factors in global and regions.
6. To analyze EGFR-TKI competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global EGFR-TKI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of EGFR-TKI and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of EGFR-TKI.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the EGFR-TKI market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global EGFR-TKI industry.
Chapter 3: Detailed analysis of EGFR-TKI manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of EGFR-TKI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of EGFR-TKI in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
205 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global EGFR-TKI Sales Value (2020-2031)
- 1.2.2 Global EGFR-TKI Sales Volume (2020-2031)
- 1.2.3 Global EGFR-TKI Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 EGFR-TKI Market Dynamics
- 2.1 EGFR-TKI Industry Trends
- 2.2 EGFR-TKI Industry Drivers
- 2.3 EGFR-TKI Industry Opportunities and Challenges
- 2.4 EGFR-TKI Industry Restraints
- 3 EGFR-TKI Market by Company
- 3.1 Global EGFR-TKI Company Revenue Ranking in 2024
- 3.2 Global EGFR-TKI Revenue by Company (2020-2025)
- 3.3 Global EGFR-TKI Sales Volume by Company (2020-2025)
- 3.4 Global EGFR-TKI Average Price by Company (2020-2025)
- 3.5 Global EGFR-TKI Company Ranking (2023-2025)
- 3.6 Global EGFR-TKI Company Manufacturing Base and Headquarters
- 3.7 Global EGFR-TKI Company Product Type and Application
- 3.8 Global EGFR-TKI Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global EGFR-TKI Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 EGFR-TKI Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 EGFR-TKI Market by Type
- 4.1 EGFR-TKI Type Introduction
- 4.1.1 Afatinib
- 4.1.2 Aumolertinib
- 4.1.3 Icotinib
- 4.1.4 Osimertinib
- 4.1.5 Dacomitinib
- 4.1.6 Erlotinib
- 4.1.7 Furmonertinib
- 4.1.8 Gefitinib
- 4.1.9 Lazertinib
- 4.1.10 Other
- 4.2 Global EGFR-TKI Sales Volume by Type
- 4.2.1 Global EGFR-TKI Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global EGFR-TKI Sales Volume by Type (2020-2031)
- 4.2.3 Global EGFR-TKI Sales Volume Share by Type (2020-2031)
- 4.3 Global EGFR-TKI Sales Value by Type
- 4.3.1 Global EGFR-TKI Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global EGFR-TKI Sales Value by Type (2020-2031)
- 4.3.3 Global EGFR-TKI Sales Value Share by Type (2020-2031)
- 5 EGFR-TKI Market by Application
- 5.1 EGFR-TKI Application Introduction
- 5.1.1 Segment by Application
- 5.1.2 Hospital and Clinic
- 5.1.3 Retail Pharmacies
- 5.1.4 Other
- 5.2 Global EGFR-TKI Sales Volume by Application
- 5.2.1 Global EGFR-TKI Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global EGFR-TKI Sales Volume by Application (2020-2031)
- 5.2.3 Global EGFR-TKI Sales Volume Share by Application (2020-2031)
- 5.3 Global EGFR-TKI Sales Value by Application
- 5.3.1 Global EGFR-TKI Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global EGFR-TKI Sales Value by Application (2020-2031)
- 5.3.3 Global EGFR-TKI Sales Value Share by Application (2020-2031)
- 6 EGFR-TKI Regional Sales and Value Analysis
- 6.1 Global EGFR-TKI Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global EGFR-TKI Sales by Region (2020-2031)
- 6.2.1 Global EGFR-TKI Sales by Region: 2020-2025
- 6.2.2 Global EGFR-TKI Sales by Region (2026-2031)
- 6.3 Global EGFR-TKI Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global EGFR-TKI Sales Value by Region (2020-2031)
- 6.4.1 Global EGFR-TKI Sales Value by Region: 2020-2025
- 6.4.2 Global EGFR-TKI Sales Value by Region (2026-2031)
- 6.5 Global EGFR-TKI Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America EGFR-TKI Sales Value (2020-2031)
- 6.6.2 North America EGFR-TKI Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe EGFR-TKI Sales Value (2020-2031)
- 6.7.2 Europe EGFR-TKI Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific EGFR-TKI Sales Value (2020-2031)
- 6.8.2 Asia-Pacific EGFR-TKI Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America EGFR-TKI Sales Value (2020-2031)
- 6.9.2 South America EGFR-TKI Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa EGFR-TKI Sales Value (2020-2031)
- 6.10.2 Middle East & Africa EGFR-TKI Sales Value Share by Country, 2024 VS 2031
- 7 EGFR-TKI Country-level Sales and Value Analysis
- 7.1 Global EGFR-TKI Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global EGFR-TKI Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global EGFR-TKI Sales by Country (2020-2031)
- 7.3.1 Global EGFR-TKI Sales by Country (2020-2025)
- 7.3.2 Global EGFR-TKI Sales by Country (2026-2031)
- 7.4 Global EGFR-TKI Sales Value by Country (2020-2031)
- 7.4.1 Global EGFR-TKI Sales Value by Country (2020-2025)
- 7.4.2 Global EGFR-TKI Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.5.2 USA EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.9.2 France EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.16.2 China EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.19.2 India EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt EGFR-TKI Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt EGFR-TKI Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt EGFR-TKI Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 ArriVent Biopharma
- 8.1.1 ArriVent Biopharma Comapny Information
- 8.1.2 ArriVent Biopharma Business Overview
- 8.1.3 ArriVent Biopharma EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.1.4 ArriVent Biopharma EGFR-TKI Product Portfolio
- 8.1.5 ArriVent Biopharma Recent Developments
- 8.2 AstraZeneca
- 8.2.1 AstraZeneca Comapny Information
- 8.2.2 AstraZeneca Business Overview
- 8.2.3 AstraZeneca EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.2.4 AstraZeneca EGFR-TKI Product Portfolio
- 8.2.5 AstraZeneca Recent Developments
- 8.3 Beacon Pharma
- 8.3.1 Beacon Pharma Comapny Information
- 8.3.2 Beacon Pharma Business Overview
- 8.3.3 Beacon Pharma EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Beacon Pharma EGFR-TKI Product Portfolio
- 8.3.5 Beacon Pharma Recent Developments
- 8.4 Boehringer Ingelheim Pharmaceuticals
- 8.4.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
- 8.4.2 Boehringer Ingelheim Pharmaceuticals Business Overview
- 8.4.3 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Product Portfolio
- 8.4.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
- 8.5 Cipla
- 8.5.1 Cipla Comapny Information
- 8.5.2 Cipla Business Overview
- 8.5.3 Cipla EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Cipla EGFR-TKI Product Portfolio
- 8.5.5 Cipla Recent Developments
- 8.6 Drug International
- 8.6.1 Drug International Comapny Information
- 8.6.2 Drug International Business Overview
- 8.6.3 Drug International EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Drug International EGFR-TKI Product Portfolio
- 8.6.5 Drug International Recent Developments
- 8.7 Glenmark Pharmaceuticals
- 8.7.1 Glenmark Pharmaceuticals Comapny Information
- 8.7.2 Glenmark Pharmaceuticals Business Overview
- 8.7.3 Glenmark Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Glenmark Pharmaceuticals EGFR-TKI Product Portfolio
- 8.7.5 Glenmark Pharmaceuticals Recent Developments
- 8.8 Hanmi Pharmaceutical
- 8.8.1 Hanmi Pharmaceutical Comapny Information
- 8.8.2 Hanmi Pharmaceutical Business Overview
- 8.8.3 Hanmi Pharmaceutical EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Hanmi Pharmaceutical EGFR-TKI Product Portfolio
- 8.8.5 Hanmi Pharmaceutical Recent Developments
- 8.9 Johnson & Johnson
- 8.9.1 Johnson & Johnson Comapny Information
- 8.9.2 Johnson & Johnson Business Overview
- 8.9.3 Johnson & Johnson EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Johnson & Johnson EGFR-TKI Product Portfolio
- 8.9.5 Johnson & Johnson Recent Developments
- 8.10 Mylan
- 8.10.1 Mylan Comapny Information
- 8.10.2 Mylan Business Overview
- 8.10.3 Mylan EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Mylan EGFR-TKI Product Portfolio
- 8.10.5 Mylan Recent Developments
- 8.11 Pfizer
- 8.11.1 Pfizer Comapny Information
- 8.11.2 Pfizer Business Overview
- 8.11.3 Pfizer EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Pfizer EGFR-TKI Product Portfolio
- 8.11.5 Pfizer Recent Developments
- 8.12 Roche
- 8.12.1 Roche Comapny Information
- 8.12.2 Roche Business Overview
- 8.12.3 Roche EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Roche EGFR-TKI Product Portfolio
- 8.12.5 Roche Recent Developments
- 8.13 Teva
- 8.13.1 Teva Comapny Information
- 8.13.2 Teva Business Overview
- 8.13.3 Teva EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Teva EGFR-TKI Product Portfolio
- 8.13.5 Teva Recent Developments
- 8.14 Yuhan Corporation
- 8.14.1 Yuhan Corporation Comapny Information
- 8.14.2 Yuhan Corporation Business Overview
- 8.14.3 Yuhan Corporation EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Yuhan Corporation EGFR-TKI Product Portfolio
- 8.14.5 Yuhan Corporation Recent Developments
- 8.15 Betta Pharma
- 8.15.1 Betta Pharma Comapny Information
- 8.15.2 Betta Pharma Business Overview
- 8.15.3 Betta Pharma EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Betta Pharma EGFR-TKI Product Portfolio
- 8.15.5 Betta Pharma Recent Developments
- 8.16 Chengdu Brilliant Pharmaceuticals
- 8.16.1 Chengdu Brilliant Pharmaceuticals Comapny Information
- 8.16.2 Chengdu Brilliant Pharmaceuticals Business Overview
- 8.16.3 Chengdu Brilliant Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Chengdu Brilliant Pharmaceuticals EGFR-TKI Product Portfolio
- 8.16.5 Chengdu Brilliant Pharmaceuticals Recent Developments
- 8.17 Hansoh Pharma
- 8.17.1 Hansoh Pharma Comapny Information
- 8.17.2 Hansoh Pharma Business Overview
- 8.17.3 Hansoh Pharma EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Hansoh Pharma EGFR-TKI Product Portfolio
- 8.17.5 Hansoh Pharma Recent Developments
- 8.18 Shanghai Allist Pharmaceuticals
- 8.18.1 Shanghai Allist Pharmaceuticals Comapny Information
- 8.18.2 Shanghai Allist Pharmaceuticals Business Overview
- 8.18.3 Shanghai Allist Pharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Shanghai Allist Pharmaceuticals EGFR-TKI Product Portfolio
- 8.18.5 Shanghai Allist Pharmaceuticals Recent Developments
- 8.19 Wanbang Biopharmaceuticals
- 8.19.1 Wanbang Biopharmaceuticals Comapny Information
- 8.19.2 Wanbang Biopharmaceuticals Business Overview
- 8.19.3 Wanbang Biopharmaceuticals EGFR-TKI Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Wanbang Biopharmaceuticals EGFR-TKI Product Portfolio
- 8.19.5 Wanbang Biopharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 EGFR-TKI Value Chain Analysis
- 9.1.1 EGFR-TKI Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 EGFR-TKI Sales Mode & Process
- 9.2 EGFR-TKI Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 EGFR-TKI Distributors
- 9.2.3 EGFR-TKI Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.